Evidence map›Paper›PMID 39746875›Full record

ReviewGut microbes2025

Assessing live microbial therapeutic transmission.

Jeremiah J Faith

Abstract readReview
In one paragraph

Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jeremiah J FaithPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

The Influence Of Gut Microbiota Stability In Inflammatory Bowel DiseaseR01DK112978 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2019 to 2026
$5.3M
Uncovering the rules of gut microbiome strain transmissionR01DK124133 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2020 to 2026
$4.2M
Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infectionR01DK130337 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAITH, JEREMIAH JAMES, GRINSPAN , ARI · 2022 to 2024
$1.0M
NIDDK NIH HHS R01 DK112978NIDDK NIH HHS R01 DK124133NIDDK NIH HHS R01 DK130337
6 · The paper itself

Abstract

The development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment of human disease has been an empirically driven process yielding a notable success of approved drugs for the treatment of recurrent

Indexed as

Clostridioides difficileClostridium InfectionsFecal Microbiota TransplantationGastrointestinal MicrobiomeAnimalsFecesHumansfecal microbiota transplantationlive biotherapeutic productmicrobial therapeuticsMicrobiomestrain tracking

Identifiers

PMID39746875
PMCPMC12931690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.